About: Antagonistes du récepteur CCR5 et infection par le VIH-1 : bases et conséquences de cette approche thérapeutique

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antagonistes du récepteur CCR5 et infection par le VIH-1 : bases et conséquences de cette approche thérapeutique Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antagonistes du récepteur CCR5 et infection par le VIH-1 : bases et conséquences de cette approche thérapeutique
Creator	Corbeau, P Psomas, K Reynes, J
Source	Medline; PMC
abstract	CCR5 molecule is a chemokine receptor with an important role in infectious diseases; not only is it the main coreceptor for HIV-1, but it has also been involved in the immune defense against various transmissible agents. CCR5 antagonists constitute a new class of antiretrovirals. Three molecules of this class have reached phases 2B and 3 of clinical development: aplaviroc (GlaxoSmithKine), vicriviroc (Schering-Plough) and maraviroc (Pfizer). The development of aplaviroc was stopped because of some cases of drug-induced hepatitis. In ACTG 5211 and Motivate trials, adding vicriviroc (in phase 3 trials) or maraviroc (now approved for clinical use) respectively to an optimized background regimen in treatment-experienced patients has resulted in a significant virologic benefit. The place of this new therapeutic class in strategies of initial, switch or rescue treatment needs further investigation, and its interest in immunological non-responders, in severe immunosuppressed patients or in subjects harbouring non-R5 HIV-1 strains, remains to be addressed. Major concerns about their use still remain, including long-term tolerability, the risk of inducing an R5 to X4 switch, particularly in compartments other than blood, and the risk of interfering with some immune responses.
has issue date	2010-02-18(xsd:dateTime)
bibo:doi	10.1016/j.antib.2010.01.006
bibo:pmid	32288525
has license	no-cc
sha1sum (hex)	b0d61d88edae2c7eed38a881e7e9da3182996e52
schema:url	https://doi.org/10.1016/j.antib.2010.01.006
resource representing a document's title	Antagonistes du récepteur CCR5 et infection par le VIH-1 : bases et conséquences de cette approche thérapeutique
has PubMed Central identifier	PMC7146793
has PubMed identifier	32288525
schema:publication	Antibiotiques (Paris)
resource representing a document's body	covid:b0d61d88edae2c7eed38a881e7e9da3182996e52#body_text
is schema:about of	named entity 'CCR5 ANTAGONISTS' named entity 'cette' named entity 'Pfizer' named entity 'substitution' named entity 'nouvelle' named entity 'CCR5' named entity 'antagonists' named entity 'CONSEQUENCES' named entity 'EST' named entity 'AVEC' named entity 'LES' named entity 'QUI' named entity 'PHASE III' covid:arg/b0d61d88edae2c7eed38a881e7e9da3182996e52 named entity 'MASSON' named entity 'SAS' named entity 'MARCH' named entity 'COR' named entity 'TOL' named entity 'PATHOLOGIE INFECTIEUSE' named entity 'PLASMA' named entity 'POUR' named entity 'CCR5' named entity 'POINTS' named entity 'APPROACH' named entity 'BASES' named entity 'SUR' named entity 'INFECTION PAR LE VIH' named entity 'THERAPEUTIC' named entity 'TERME' named entity 'APLAVIROC' named entity 'MOL' named entity 'CCR5' named entity 'INITIAL' named entity 'AAME' named entity 'PLUSIEURS' named entity 'PAR' named entity 'MOTIVATE' named entity 'IIB' named entity 'INT' named entity 'LONG' named entity 'QUE' named entity 'AAT' named entity 'MISE' named entity 'VIH' named entity 'CONSTITUENT' named entity 'TRAITEMENT' named entity 'ESSAIS' named entity 'NON-' named entity 'III' named entity 'VICRIVIROC' named entity 'SUBSTITUTION' named entity 'ONT' named entity 'IMPORTANT' named entity 'UNE' named entity 'MARAVIROC' named entity 'ACTG' named entity 'DES' named entity 'PATIENTS' named entity 'CHEZ' named entity 'INFECT' named entity 'NOUVELLE' named entity 'DISCORDANCE' named entity 'HIV-1 INFECTION' named entity 'STRAT' named entity 'PHASES' named entity 'JOUE' named entity 'Motivate' named entity 'Tous' named entity 'ont' named entity 'maraviroc' named entity 'constituent' named entity 'vicriviroc' named entity 'plasma' named entity 'les' named entity 'Bases' named entity 'par' named entity 'Pfizer' named entity 'maraviroc'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software